The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry

Abstract In patients with myelodysplastic syndrome (MDS), the prognostic significance of chromosome 17 abnormalities has not yet been fully elucidated, except for isochromosome 17q that has been characterized as an intermediate risk abnormality in the Revised International Prognostic Scoring System...

Full description

Bibliographic Details
Main Authors: Panagiotis Diamantopoulos, Dafni Koumbi, Ioannis Kotsianidis, Vasiliki Pappa, Argiris Symeonidis, Athanasios Galanopoulos, Panagiotis Zikos, Helen A. Papadaki, Panayiotis Panayiotidis, Maria Dimou, Eleftheria Hatzimichael, George Vassilopoulos, Susan Delimpasis, Despoina Mparmparousi, Sotirios Papageorgiou, Eleni Variami, Marie‐Christine Kyrtsonis, Aekaterini Megalakaki, Maria Kotsopoulou, Panagiotis Repousis, Ioannis Adamopoulos, Flora Kontopidou, Dimitrios Christoulas, Alexandra Kourakli, Dimitrios Tsokanas, Menelaos Konstantinos Papoutselis, Georgios Kyriakakis, Nora‐Athina Viniou, the Hellenic MDS study group
Format: Article
Language:English
Published: Wiley 2019-05-01
Series:Cancer Medicine
Subjects:
5‐azacytidine
chromosome 17 abnormality
myelodysplastic syndrome
Online Access:https://doi.org/10.1002/cam4.2090

Internet

https://doi.org/10.1002/cam4.2090

Similar Items